Jinwon Life Sciences Begins Evaluation Study on Oral COVID-19 Treatment Drug's Efficacy in Treating Aftereffects

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 31st that it has decided to evaluate the efficacy of GLS-1027 (Zenuzolak) for the treatment and prevention of long COVID (post-COVID-19 syndrome) and has signed a joint research agreement with the Wistar Institute in the United States for this purpose.

The study is a multipart assessment trial to prevent long COVID after acute infection recovery or to treat long COVID patients by administering GLS-1027 during the early stage of infection in severe patients hospitalized due to the COVID-19 virus. It is being conducted jointly with Dr. Mohamed Abdel-Mohsen, a long COVID research expert at the Wistar Institute.

Based on the results of this study, GeneOne Life Science plans to verify whether early administration of GLS-1027 prevents the occurrence of long COVID in hospitalized patients with acute COVID-19 infection in the global Phase 2 clinical trial of GLS-1027, an oral COVID-19 treatment under development.

To this end, the company has also decided to collaborate with the University of California at San Francisco consortium, which leads global research on HIV and COVID-19 virus treatments and is pioneering long COVID therapeutics.

GLS-1027 is an oral low-molecular-weight immunomodulator that suppresses the production of inflammatory cytokines that cause a ‘cytokine storm,’ which worsens the condition of patients due to inflammation upon COVID-19 diagnosis. GLS-1027 induced a reduction in pneumonia symptom markers in a hamster aggressive infection model and was confirmed to significantly reduce virus-induced syncytia and atypia, pathological features of severe pneumonia.

The company explained, “Researchers at the Wistar Institute and the University of California at San Francisco discovered biomarkers predicting the onset of post-COVID-19 syndrome through metabolomics studies precisely conducted on COVID-19 confirmed patients.”

Park Young-geun, CEO of GeneOne Life Science, said, “If this study proves the potential of GLS-1027 to prevent or treat long COVID, it will provide significant help to millions of patients experiencing long COVID symptoms,” adding, “We plan to expand this study into a clinical trial using the global Phase 2 clinical trial of GLS-1027 to develop GLS-1027 as a potential official long COVID treatment.”

This content was produced with the assistance of AI translation services.